News

A fast track designation from the FDA has been given to PT886 for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma.

Ramez N. Eskander, MD, discusses additional targetable biomarkers that could be addressed in a similar combination as what was seen in the phase 3 NRG-GY018/KEYNOTE-868 trial with standard of care chemotherapy.

The combination of pembrolizumab and olaparib did not appear to improve overall or progression-free survival in patients with nonsquamous non-small cell lung cancer.

The frontline standard-of-care regimen for patients with higher-risk MDS and some with lower-risk MDS remain hypomethylating agents, such as azacitidine, decitabine, and decitabine/cedazuridine.

Thomas J. Herzog, MD, discusses the efficacy data seen in a subgroup analysis of the phase 2 AMPECT study evaluating nab-Sirolimus for patients with perivascular epithelioid sarcoma.

Carlos Rojas, MD, discusses the next steps for evaluating MK-1084 in a phase 1 trial for the first-line treatment of metastatic non-small cell lung cancer and advanced solid tumors.

ctDNA offers clinicians the potential to determine whether to proceed with or discontinue PARP inhibitor maintenance therapy in patients with recurrent epithelial ovarian cancer.

Thomas J. Herzog, MD, discusses the safety findings of nab-Sirolimus in a subgroup analysis of the phase 2 AMPECT study looking at patients with perivascular epithelioid sarcoma.

APL-1702 is the first nonsurgical treatment for cervical high-grade intraepithelial lesions to show clinical efficacy in a phase 3 trial, making it a potentially groundbreaking option in the field.

Thomas J. Herzog, MD, discusses the importance of patients seeing a gynecologist oncologist or a sarcoma doctor for gynecologic perivascular epithelioid sarcomas.

Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.

The FDA fast-tracked MVR-T3011, an intratumorally injected oncolytic virus, for treating recurrent or metastatic head and neck squamous cell cancer post-platinum chemotherapy and at least 1 prior anti-PD1/PDL1 therapy.

In an interview with Targeted Oncology, Robert Reid, MD, discussed how the utilization of Ontada’s solutions helps to improve community-based research across the field of oncology.

The phase 3 CheckMate -9DW study of frontline nivolumab plus ipilimumab in hepatocellular cancer met its primary end point of overall survival vs sorafenib or lenvatinib.

Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.

The latest developments across the field of gynecologic oncology were presented at the 2024 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer in San Diego, California, from March 16-18, 2024.

Rezatapopt treatment delivered responses with acceptable toxicity in heavily pretreated patients with advanced ovarian cancer harboring TP53 Y220C mutations.

Findings from the DUO-E study support potential new durvalumab-based treatment options for patients with advanced or recurrent endometrial cancer.

Ponatinib in combination with chemotherapy is now an approved treatment option for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

In the phase 3 LEAP-001, the combination of lenvatinib plus pembrolizumab improved progression-free survival and overall survival among patients with endometrial cancer.

Camrelizumab, nab-paclitaxel, and cisplatin showed statistically significant enhancements in pathologic complete responses in patients with resectable locally advanced esophageal squamous cell carcinoma.

Ariel Lopez-Chavez, MD, discusses some of the research on evaluating PD-L1 therapy for patients with small cell lung cancer.

March is Multiple Myeloma Awareness Month and experts like Amrita Krishnan, MD, and Adam D. Cohen, MD, explained the positive impact CAR T-cell therapies and bispecific antibodies have had in the space.

If approved, denileukin diftitox could offer a valuable addition to the treatment landscape of relapsed/refractory cutaneous T-cell lymphoma.

The use of ChatGPT may help to improve genetic counseling for patients with gynecologic cancer.

P-BCMA-ALLO1 was granted an FDA orphan drug designation for the treatment of patients with relapsed/refractory multiple myeloma and is being evaluated in a phase 1 trial.

In patients with advanced melanoma, lifileucel showed durable efficacy and a 4-year overall survival rate of 21.9%, according to long-term findings from the phase 2 C-144-01 trial.

An increased risk of death and lower enrollment in clinical trials have been observed between Black and White patients with endometrial cancer.

This week's Targeted Pulse focuses on the latest in the treatment landscapes of small cell lung cancer, myeloma, and more.